GSK 2024 Financial Results: Oncology Sales Surge by 98%, Vaccine Segment Enters Slump Period (with PPT)

Feb 06, 2025 07:00 CST Updated 07:00

GSK

Pharmaceutical R&D Manufacturer

On February 5, GSK announced its financial results for 2024. The company's total revenue for the year was £31.376 billion, representing a year-on-year increase.8%Looking ahead to 2025, GSK expects its total annual revenue to increase by 3%-5%.

1. Financial Performance

Total Revenue in 2024: £31.376 billion, an increase of 8% year-on-year
Core Operating Profit: £9.148 billion, a year-on-year increase of 13%
Cash Flow from Operating Activities: £7.9 billion
Free Cash Flow: £2.9 billion
R&D Investment: £6.023 billion, a year-on-year increase of 7%

2. Business Performance

Special Drugs: Sales increased by 19%, contributing to over 70% of the revenue growth.
Vaccine: Sales decreased by 3%
Common Medicines: Sales increased by 6%
HIV Drugs: Sales increased by 13% to reach £7.089 billion
Respiratory System / Immunology Drugs: Sales increased by 12%, with strong performances from Nucala and Benlysta.
Oncology Drugs: Sales increased by 17%, with Zejula and Jemperli performing particularly well.

3. R&D Progress

Special Drugs：

Blenrep: Demonstrates significant overall survival benefits in the treatment of multiple myeloma
depemokimab: Demonstrated outstanding performance in severe asthma and chronic rhinosinusitis with nasal polyps, with plans to initiate a Phase 3 trial for COPD in 2025.
Nucala: Phase 3 trials in COPD are ongoing

Vaccine：

Arexvy (RSV Vaccine): Positive data obtained in high-risk adults aged 18-49
MenABCWY Vaccine: Expected to receive FDA approval in 2025

HIV Drugs：

Cabenuva and Apretude: Long-acting injectables continue to grow
cabotegravir: Plan to launch Q4M PrEP study in 2025

Respiratory, Immunology and Inflammation：

camlipixant: Demonstrates excellent performance in the treatment of refractory chronic cough, with data expected to be released in 2025.
IL-33 and TSLP: Phase 3 trial planned to start in 2027